Latest news ...

Some of our recent news articles.

 
08
August
2019
08th August 2019
 

Pfizer expected to announce stock deal with Mylan

 Deal would cover former blockbuster brands like Lipitor and Viagra, both made in Ireland

 
Read the full story »
 
 
07
August
2019
07th August 2019
 

Mylan and Upjohn, a Division of Pfizer to Combine

Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine

 
Read the full story »
 
 
29
July
2019
29th July 2019
 

Pfizer expected to announce stock deal with Mylan

Deal would cover former blockbuster brands like Lipitor and Viagra, both made in Ireland

 
Read the full story »
 
 
22
May
2018
22nd May 2018
 

Up to 25,000 pharma jobs if EU alters patent rules

Mylan boss calls for waiver on manufacturing of biosimilars
 
Read the full story »
 
 
16
August
2017
16th August 2017
 

Mylan slashes earnings forecast on US generics price cuts

Earnings undershoot forecasts in second quarter despite acquisitions
 
Read the full story »
 
 
30
March
2017
30th March 2017
 

Mylan's generic Advair gets stiff-armed by FDA. What does this mean for GSK?

Mylan’s FDA decision date for its knockoff of GlaxoSmithKline respiratory blockbuster Advair came and went Tuesday, with no word from the drugmaker or regulators. But Wednesday afternoon, Mylan finally said its copycat had been turned away.
 
Read the full story »
 
 
26
August
2016
26th August 2016
 

Mylan listens to Hillary Clinton and cuts EpiPen price

Company had increased cost of allergy device to $600 for two shots
 
Read the full story »
 
 
03
May
2016
03rd May 2016
 

Mylan tops 1Q profit forecasts

Mylan beats 1Q net income expectations, misses revenue forecasts
 
Read the full story »
 
 
03
May
2016
03rd May 2016
 

Failed Perrigo suitor Mylan sees revenues rise on generic drugs

Dutch-domiciled US group says it is still fully committed to planned $7.2bn takeover of Sweden’s Meda
 
Read the full story »
 
 
11
February
2016
11th February 2016
 

Mylan, the generic drugmaker, is poised to announce a takeover of Sweden’s Meda, according to people briefed on the deal.

The takeover of Meda would have a market value of roughly SEK 31.4 billion (€3.3 billion).
 
Read the full story »
 
 
16
November
2015
16th November 2015
 

Mylan admits that bid for Dublin-based Perrigo has failed

Generic drug maker Mylan said on Friday that 40 per cent of Perrigo ’s shares were tendered in its $26 billion hostile takeover offer, falling short of the goal of 50 per cent.
With the deadline for the offer expiring on Friday, Mylan said 58 million Perrigo ordinary shares had been validly tendered.
 
Read the full story »
 
 
08
September
2015
08th September 2015
 

Mylan to ask Perrigo shareholders to accept $27.1bn takeover

Mylan has said it plans to start its $27.1 billion takeover of Dublin-based Perrigo on Monday next, asking shareholders of the over-the-counter drug maker to accept a proposal that the company’s executives have refused.
 
Read the full story »
 
 
31
August
2015
31st August 2015
 

Mylan ready to make $33 billion hostile bid for Perrigo

Mylan’s shareholders voted in favour of moving forward with a $33 billion (€29.5 billion) hostile bid for over-the-counter pharma group Perrigo, putting the fate of the deal in the hands of Perrigo investors.
 
Read the full story »
 
 
24
August
2015
24th August 2015
 

Mylan shareholders to vote on Perrigo acquisition

Mylan seeks to acquire Perrigo in a $36bn deal opposed by Perrigo’s board of directors
 
Read the full story »
 
 
13
August
2015
13th August 2015
 

Mylan defends way it saw off hostile takeover

Mylan, the generic drugs group, has launched a staunch defence of the tactics it used to repel a $40 billion hostile takeover attempt by Teva, amid pockets of shareholder unrest over the company’s handling of the approach.
 
Read the full story »
 
 
 
 
 
 
 
 
 

About Us

SURIMS is the new name for Actex Pharma Services which was a consultancy established in 2003, supporting companies in the identification, qualification and management of quality vendors and suppliers in ingredients and formulations.

The Pharmaceutical Services Directory supports the identification and on-boarding of quality suppliers and also incorporates software features that manage relationships between suppliers and their customers. These include the building and deployment of questionnaires and assessments, electronic signatures and sign-offs and project management between vendor/partner and customer.

Access to the features and software is available on a 'pay as you go' basis, or a customised version can be licensed for your company for its own supplier on-boarding and supplier management activities. Further information on our software services please contact Tel: +353 87 294 0436 or email info@pharmaservicesdirectory.com

 
 
 

Get in Touch

The Pharmaceutical Services Directory
info@pharmaservicesdirectory.com.

 
 

© 2019 Actex Pharma Services | All Rights Reserved.